ApoA-I-Directed Therapies for the Management of Atherosclerosis

作者：Millar John S; Cuchel Marina^*

来源：Current Atherosclerosis Reports, 2015, 17(10): 60.

DOI：10.1007/s11883-015-0539-0

• HDL
• ApoA-I
• PPAR
• LXR
• Apolipoproteins
• Lipoproteins

Several recent reports have raised doubts about the atheroprotective role of high-density lipoprotein cholesterol (HDL-C). Nevertheless, a substantial body of work supports the validity of pharmacological interventions able to enhance HDL function, as opposed to raising HDL-C levels per se. In this article, we briefly review the development of pharmacological interventions that target apoA-I and HDL function as a means of reducing atherosclerotic risk: small molecule pharmaceuticals, small HDL mimetic peptides, and infusion of apoA-I-containing particles.

• 出版日期2015-10